Wall Street Fundamentals Releases New In-Depth Stock Reports on ARRY, INFI, ISIS and NVAX
The Biotech Industry has skyrocketed in the past year as faster approval processes have led to an increase in new drug approvals. The U.S. Food and Drug Administration approved a total of 39 new drugs in 2012, the second highest total since 1996. The NASDAQ Biotech Index (NASDAQ: NBI) and the SPDR S&P Biotech ETF (NYSE: XBI) have seen gains of approximately 46 percent and 37 percent, respectively, in the past year, while the NASDAQ and S&P 500 Index have posted gains of 23 percent and 25.5 over the same period.
Array Biopharma Inc. (NASDAQ: ARRY) shares traded in the range of $5.81 to $6.06 Friday before settling to close at $5.84, a decrease of 2.5 percent. The stock appears to be facing resistance at $5.88 with some support at $5.42. The company is scheduled to present at the Jefferies 2013 Global Healthcare Conference in New York City on Tuesday, June 4th. Shares of Array Biopharma have gained approximately 70 percent in the past year.
More information on Array Biopharma and access to the free equity report can be found at: www.WallStreetFundamentals.com/ARRY
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares traded in the range of $26.82 to $29.13 Friday before settling to close at $26.95, a decrease of 7.0 percent. The stock appears to be facing resistance at the $30.61 and $33.19 levels. The company recently announced early data from an ongoing study of IPI-145, as a treatment for chronic lymphocytic leukemia, showed that IPI-145 was well tolerated, with a rapid onset of clinical activity. Shares ofInfinity Pharmaceuticals have gained approximately 125 percent in the past year.
More information on Infinity Pharmaceuticals and access to the free equity report can be found at: www.WallStreetFundamentals.com/INFI
ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) shares traded in the range of $21.57 to $22.05 Friday before settling to close at $21.69. The stock appears to be facing some resistance at the $22.87 with support at $20.91. The company last month announced it has earned a $3.5 million milestone payment from Biogen Idec after the dosing the first patient in a Phase 2 study of ISIS-SMN. Shares of ISIS Pharmaceuticals have gained approximately 120 percent in the past year.
More information on ISIS Pharmaceuticals and access to the free equity report can be found at: www.WallStreetFundamentals.com/ISIS
Novavax, Inc. (NASDAQ: NVAX) shares traded in the range of $1.89 to $2.06 Friday before settling to close at $1.91, a decrease of 5.45 percent. The stock appears to have some resistance at $1.95 with reasonable support at $1.90. The company has announced that its H7N9 VLP influenza vaccine has entered animal testing.Shares of Novavax have gained approximately 55 percent in the past year.
More information on Novavax and access to the free equity report can be found at: www.WallStreetFundamentals.com/NVAX
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer:
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain
information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Contact: Wall Street Fundamentals Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com